Quality of anticoagulant therapy and the incidence of in-stent thrombosis after venous stenting

Pascale Notten, Jorinde H. H. van Laanen, Pieter Eijgenraam, Mark A. F. de Wolf, Ralph L. M. Kurstjens, Hugo ten Cate, Arina J. ten Cate-Hoek*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

Background: In patients with a venous outflow obstruction following iliofemoral deep vein thrombosis stenting of the venous tract to prevent or alleviate postthrombotic syndrome is applied with increasing frequency. The impact of the quality of anticoagulant therapy with vitamin K antagonists (VKAs) on the development of in-stent thrombosis is currently unknown.

Objectives: To determine the association between the quality of postinterventional VKA treatment and the occurrence of in-stent thrombosis.

Methods: Seventy-nine patients with iliofemoral and/or caval venous stent placement for obstruction of the venous outflow were included in this study. All patients received postinterventional VKA. The quality of VKA anticoagulant therapy was expressed as the time within therapeutic range (TTR) calculated using the linear interpolation method and as the proportion of International Normalized Ratio (INR) values <2.0. In-stent thrombosis was assessed by the use of duplex ultrasound. Survival analysis (Kaplan-Meier curves, Cox regression) was used to analyze the data.

Results: In-stent thrombosis developed in 16 patients (20.3%). The total population had a mean TTR of 64.0% (19.0) and a mean proportion of INR values <2.0 of 11.6% (+/- 12.0). Overall, a TTR <49.9% was associated with an increased risk of in-stent thrombosis. The multivariable adjusted analysis showed a hazard ratio (HR) of 0.96 (95% confidence interval [CI], 0.92-0.99; P = .02) per 1% increase in TTR. The proportion of INR values <2.0 had no significant association with the occurrence of in-stent thrombosis: HR 0.98 (95% CI, 0.91-1.06; P = .66).

Conclusions: We conclude that the quality of anticoagulant treatment reflected in the TTR following a venous stenting procedure is an important independent determinant for the risk of in-stent thrombosis. The role of anticoagulant treatment for the prevention of in-stent thrombosis following stenting procedures therefore merits further research.

Original languageEnglish
Pages (from-to)594-603
Number of pages10
JournalResearch and practice in thrombosis and haemostasis
Volume4
Issue number4
DOIs
Publication statusPublished - May 2020

Keywords

  • anticoagulants
  • deep vein thrombosis
  • International Normalized Ratio
  • postthrombotic syndrome
  • stents
  • DEEP-VEIN THROMBOSIS
  • CATHETER-DIRECTED THROMBOLYSIS
  • POSTTHROMBOTIC SYNDROME
  • ANTITHROMBOTIC THERAPY
  • THROMBOEMBOLISM
  • WARFARIN
  • RIVAROXABAN
  • OUTFLOW
  • EPISODE
  • DISEASE

Cite this